Evidence map›Paper›PMID 38288195›Full record

ReviewCureus2023

A Systematic Review of the Neuroprotective Effects of Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy and Diabetic Macular Edema: Unraveling the Molecular Mechanisms and Clinical Implications.

Mansi Yadav, Han Grezenko, Venkata Madusudana Rao Kanukollu, Abdur Rehman, Syed Faqeer Hussain Bokhari, Taufiqa Reza, Carlos D Franco, Srikar P Chilla, Hira Fatima, Jinal Choudhari and 3 more

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Diabetic retinopathy and Alzheimer's disease: Convergence of the unfolded protein response in neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Mansi YadavInternal Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, IND.
Han GrezenkoTranslational Neuroscience, Barrow Neurological Institute, Phoenix, USA.
Venkata Madusudana Rao KanukolluOphthalmology, Stoke Mandeville Hospital, Aylesbury, GBR.
Abdur RehmanSurgery, Mayo Hospital, Lahore, PAK.
Syed Faqeer Hussain BokhariSurgery, King Edward Medical University, Lahore, PAK.
Taufiqa RezaMedicine, Avalon University School of Medicine, Youngstown, USA.
Carlos D FrancoMedicine, Universidad Laica Eloy Alfaro, Manta, ECU.
Srikar P ChillaMedicine, Care Hospitals, Hyderabad, IND.
Hira FatimaInternal Medicine, Rawalpindi Medical University, Rawalpindi, PAK.
Jinal ChoudhariResearch and Academic Affairs, Larkin Community Hospital, Miami, USA.
Noor Abdullah YahyaMedicine, Dubai Medical College, Dubai, ARE.
Maaz AmirInternal Medicine, King Edward Medical University, Lahore, PAK.
Syed Naveed MohsinOrthopedics, St James Hospital, Dublin, IRL.
King Edward Medical University · PKLarkin Community Hospital · USMayo Hospital · PKPandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences · INRawalpindi Medical University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a leading cause of global visual impairment, necessitating a comprehensive understanding of its vascular and neural components for effective therapeutic interventions. While vascular pathology is well-established, recent evidence suggests a neurodegenerative role in DR. Vascular endothelial growth factor (VEGF), traditionally implicated in angiogenesis, has emerged as a key player with neuroprotective potential. This systematic review evaluates the literature to shed light on molecular mechanisms and clinical implications in this regard. The review adheres to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, encompassing a thorough search strategy across multiple databases. Three in vitro studies met the inclusion criteria, highlighting the limited research in this evolving field. Findings suggest VEGF's neuroprotective effects on retinal ganglion cells (RGCs) and retinal neurons, unveiling potential therapeutic avenues. However, concerns arise regarding anti-VEGF therapies' impact on RGC survival. The review discusses the need for further research to delineate specific isoforms and signaling pathways responsible for VEGF-mediated neuroprotection. The delicate balance between angiogenesis and neuroprotection poses challenges in therapeutic development, emphasizing the importance of targeted interventions. Despite limitations, this review provides valuable insights into the intricate relationship between VEGF and neuroprotection in DR, paving the way for future investigations and redefining therapeutic strategies.

Indexed as

angiogenesisclinical implicationsdiabetic retinopathymolecular mechanismsneuroprotectionretinal ganglion cellssystematic reviewtherapeutic strategiesvascular endothelial growth factorvegf

Identifiers

PMID38288195
PMCPMC10824587
OpenAlexW4390457699

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.